ISRCTN41579286 https://doi.org/10.1186/ISRCTN41579286

PRIMETIME – Post-operative avoidance of radiotherapy in minimal risk women: patient selection using biomarkers

Submission date 30/01/2017	**Recruitment status** No longer recruiting	[X] Prospectively registered [X] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [X] Record updated in last year
Registration date 07/03/2017	**Overall study status** Ongoing	
Last Edited 27/11/2025	**Condition category** Cancer	

Plain English summary of protocol
https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/study-radiotherapy-women-small-risk-breast-cancer-returning-primetime

Contact information

Type(s)
Public

Contact name
Ms Lorna Smith

Contact details
Sir Richard Doll Building
15 Cotswold Road
Sutton
Surrey
United Kingdom
SM2 5NG
+44 208 722 4054
primetime-icrctsu@icr.ac.uk

Additional identifiers

Integrated Research Application System (IRAS)
190307

Central Portfolio Management System (CPMS)
33217

Study information

Scientific Title
Post-operative avoidance of radiotherapy: biomarker selection of women categorised to be in a very low risk group by IHC4+C

Acronym
PRIMETIME

Study objectives
The aim of this study is to test whether radiotherapy can be safely avoided in a patient population considered to have such a low risk of local recurrence that the potential absolute gain from radiotherapy is so small as to not outweigh the established risks associated with breast radiotherapy.

Ethics approval required
Old ethics approval format

Ethics approval(s)
East of England – Cambridgeshire and Hertfordshire Research Ethics Committee, 05/09/2016, ref: 16/EE/0305

Primary study design
Interventional

Study design
Non-randomized; Interventional; Design type: Treatment, Radiotherapy, Management of Care

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Breast cancer

Interventions
Patients consent and register for pre-screening Ki67 research testing and 5 slides from the diagnostic block are forwarded for analysis to the central laboratory. Breast conserving surgery will proceed according to standard practice. If a patient is confirmed as eligible (meets inclusion and exclusion criteria) they will then be consented for the main PRIMETIME study. The IHC4+C calculator is then utilised to direct treatment according to the patient's risk category (i.e. if they are deemed 'very low risk' they will be recommended to avoid radiotherapy). All patients will then receive either standard breast radiotherapy or no radiotherapy and standard adjuvant hormone therapy and any additional anti-cancer treatments.

For patients who receive radiotherapy they will have 5 years of annual mammograms, for patients who do not receive radiotherapy they will be required to attend for 10 years of annual mammograms. Patients will be followed up for 10 years in clinic and thereafter via routine data sources.

Added 27/11/2025:
Additional Data Linkage Information:
Participants from this trial will also be included in the INTERACT project which will link to their data held by NHS England. For more information, please see the INTERACT website: https://www.icr.ac.uk/interact.

Intervention Type
Other

Primary outcome(s)
Ipsilateral breast local relapse rate 5 years from study registration is assessed through patient note review.

Key secondary outcome(s)
1. Ipsilateral breast local relapse rate is measured by patient note review 10 years from study registration
2. Regional relapse rate is measured by patient note reviewat 5 and 10 years
3. Distant relapse rate is measured by patient note review at 5 and 10 years
4. Overall survival is measured by patient note review at 5 and 10 years
5. Breast cancer specific survival is measured by patient note review at 5 and 10 years

Completion date
19/05/2030

Eligibility

Key inclusion criteria
1. Provision of written informed consent to participate in the PRIMETIME study
2. Provision of slides for research testing and availability of KI67 result (contact ICR-CTSU to confirm)
3. Women aged ≥60 years (younger patients are eligible if they are post-menopausal and have co-morbidities that imply a high risk of radiotherapy toxicity e.g. significant cardiovascular disease with left sided breast cancer)
4. Women having had breast conserving surgery with complete resection of tumour tissue (≥1 mm microscopic, circumferential margins of normal tissue from invasive cancer and DCIS)
5. AJCC staging of pT1/pN0/M0 (DCIS is allowed in combination with invasive breast cancer; isolated tumour cells in axillary nodes are allowed)
6. Histological confirmation of grade 1 or 2 invasive breast cancer
7. Oestrogen receptor (ER) positive according to local practice. The H score must be available.
8. Progesterone receptor (PR) positive according to local practice. The percentage positivity must be available.
9. Human epidermal growth factor receptor (HER2) negative according to local practice
10. Patients must be recommended for ≥5 years adjuvant endocrine therapy according to local policy and in the investigator’s opinion, deemed able to comply with the duration of treatment

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Sex
Female

Total final enrolment
0

Key exclusion criteria
1. Patients known to have lymphovascular space invasion and/or axillary nodal micrometastases or macrometastases.
2. Patients with a past history of malignancy excep:
2.1. Basal cell skin cancer and CIN cervix uteri
2.2.Treated, localised squamous cell carcinoma of the skin
2.3. Malignancies treated with curative intent and the patient has been disease free ≥5 years
3. Patients who have had an ipsilateral mastectomy
4. Patients who have received neoadjuvant therapy (endocrine or cytotoxic chemotherapy with therapeutic intent) or who are deemed by the MDT to require adjuvant cytotoxic chemotherapy
5. Patients with mammographically occult breast cancers, ie. present with lump, but not visible on mammogram

Date of first enrolment
17/03/2017

Date of final enrolment
28/02/2022

Locations

Countries of recruitment
United Kingdom

England

Scotland

Wales

Study participating centre
Addenbrookes Hospital
Hills Road
Cambridge
England
CB2 0QQ

Study participating centre
Raigmore Hospital
Old Perth Road
Inverness
Scotland
IV2 3UJ

Study participating centre
Wrexham Maelor
Cresnewydd Road
Wrexham
Wales
LL13 7TD

Study participating centre
Norfolk and Norwich University Hospital
Colney Lane
Norwich
England
NR4 7UY

Study participating centre
Barts Hospital
W Smithfield
London
England
EC1A 7BE

Study participating centre
Royal Free Hospital
Pond Street
London
England
NW3 2QG

Study participating centre
Mount Vernon Hospital
Rickmansworth Road
Northwood
England
HA6 2RN

Study participating centre
Lister Hospital
Coreys Mill Lane,
Stevenage
England
SG1 4AB

Study participating centre
Queen Elizabeth II Hospital
Howlands
Welwyn Garden City
England
AL7 4HQ

Study participating centre
Charing Cross Hospital
Fulham Palace Road
London
England
W6 8RF

Study participating centre
University Hospital of South Manchester
Southmoor Road,
Wythenshawe
Manchester
England
M23 9LT

Study participating centre
Churchill Hospital
Old Road,
Headington
Oxford
England
OX3 7LE

Study participating centre

The Hillingdon Hospital
Pield Heath Road
Uxbridge
England
UB8 3NN

Study participating centre
Clatterbridge Cancer Centre
Clatterbridge Health Park,
Clatterbridge Road,
Birkenhead
Wirral
England
CH63 4JY

Study participating centre
The Royal Marsden
203 Fulham Road
London
England
SW3 6JJ

Study participating centre
The Royal Marsden
Downs Road
Sutton
England
SM2 5PT

Study participating centre
The Royal Bournemouth Hospital
Castle Lane East
Bournemouth
England
BH7 7DW

Study participating centre
Royal Glamorgan Hospital
Ynysmaerdy

Llantrisant
Wales
CF72 8XR

Study participating centre
Musgrove Park Hospital
Parkfield Drive
Taunton
England
TA1 5DA

Study participating centre
West Suffolk Hospital
Hardwick Lane
Bury Saint Edmunds
England
IP33 2QZ

Sponsor information

Organisation
Institute of Cancer Research

ROR
https://ror.org/043jzw605

Funder(s)

Funder type
Charity

Funder Name
Cancer Research UK

Alternative Name(s)
CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type
Private sector organisation

Funding Body Subtype
Other non-profit organizations

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No
Interim results article		14/06/2021	13/08/2021	Yes	No
Protocol file	version v3.0	03/05/2019	16/03/2021	No	No
Protocol file	version 4.0	13/01/2021	07/11/2023	No	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes